Recent

% | $
Quotes you view appear here for quick access.

SIGA Technologies Inc. Message Board

  • nicehedges nicehedges Aug 5, 2013 2:54 PM Flag

    EID Journal: Dengue Vaccine Failure

    Volume 19, Number 8—August 2013
    To the Editor: Dengue is one of the most widespread infectious diseases globally; transmission now occurs in 128 countries. Although dengue virus (DENV) control strategies have targeted vector control and disease surveillance, the development of an effective vaccine is the holy grail of prevention.
    Dengue vaccine development has spanned many decades. A candidate vaccine (Sanofi Pasteur, Swiftwater, PA, USA) containing all 4 DENV serotypes is in advanced clinical testing. However, when given to school children in Thailand, this live-attenuated, tetravalent, dengue–yellow fever 17D chimeric virus vaccine showed major but incomplete efficacy against 3 of the 4 DENV serotypes (DENV 1 [61.2%], DENV-3 [81.3%], and DENV-4 [89.9%]) in the intention-to-treat group but no protection against DENV 2, the most pathogenic of the DENV serotypes (1).

 
SIGA
2.050.0000(0.00%)Mar 19 4:00 PMEDT